AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16364049 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (both dosages)
Number of subjects: 24
Study 12063585 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture YNSA basis-point D
Number of subjects: 42
Study 12063585 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at the classical point Xiao Chang Shu = Bl 27
Number of subjects: 42
Study 12063585 — intervention group
Group type: COMPARATOR
Intervention: Placebo point of the head
Number of subjects: 42
Study 12063585 — intervention group
Group type: COMPARATOR
Intervention: Placebo point of the gluteal region
Number of subjects: 42
Study 9598622 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g co-amoxiclav intravenously followed by three further doses of oral co-amoxiclav (Group 1)
Number of subjects: 83
Study 9598622 — intervention group
Group type: COMPARATOR
Intervention: 1.2 g co-amoxiclav intravenously (Group 2)
Number of subjects: 83
Study 7712689 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training alone (n = 18)
Number of subjects: 44
Study 7712689 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training in combination with selected resistance exercises (n = 17)
Number of subjects: 44
Study 7712689 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group (n = 9)
Number of subjects: 44
Study 2472988 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of pirenzepine (PZ) intravenously every 12 hours
Number of subjects: 115
Study 2472988 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of pirenzepine (PZ) intravenously every 12 hours
Number of subjects: 115
Study 2472988 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pirenzepine)
Number of subjects: 115
Study 309031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold cardioplegic method (Group A) - 4 degrees C. asanguineous solution with 30 mEq. of potassium per liter infused into the aortic root for about 2 minutes after aortic cross-clamping and again after 45 minutes or when myocardial temperature rose above 19 degrees C.
Number of subjects: 34
Study 309031 — intervention group
Group type: COMPARATOR
Intervention: Simple cardiac cooling by hypothermic systemic perfusion before aortic cross-clamping plus external cardiac cooling (Group B).
Number of subjects: 34
Study 31651605 — intervention group
Group type: EXPERIMENTAL
Intervention: Mine workers
Number of subjects: 1169
Study 31651605 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 1169
Study 28113105 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention for stuttering (7-day duration)
Number of subjects: 39
Study 25842727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention and oral administration of Chinese medicine (Group A)
Number of subjects: 90
Study 25842727 — intervention group
Group type: COMPARATOR
Intervention: Intervention alone (Group B)
Number of subjects: 90
Study 25842727 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Chinese medicine only (Group C)
Number of subjects: 90
Study 23926681 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose testosterone undecanoate capsules combined with tadalafil
Number of subjects: 90
Study 23926681 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil
Number of subjects: 90
Study 21842020 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium toothbrushes
Number of subjects: 25
Study 21842020 — intervention group
Group type: COMPARATOR
Intervention: Soft toothbrushes
Number of subjects: 25
Study 19894377 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 95
Study 19894377 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus Fluoxetine
Number of subjects: 95
Study 17444512 — intervention group
Group type: EXPERIMENTAL
Intervention: Early screening
Number of subjects: 351
Study 17444512 — intervention group
Group type: COMPARATOR
Intervention: Traditional external review
Number of subjects: 351
Study 17444512 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 351
Study 14991552 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month ankle-strengthening and walking program
Number of subjects: 81
Study 14991552 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 12566672 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous cuff interposition
Number of subjects: 40
Study 12566672 — intervention group
Group type: COMPARATOR
Intervention: Control (no venous cuff)
Number of subjects: 40
Study 9821903 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose laser therapy (5J/cm2)
Number of subjects: 217
Study 9821903 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose laser therapy (0.5J/cm2)
Number of subjects: 217
Study 9821903 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser therapy (0J/cm2)
Number of subjects: 217
Study 8021909 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (1, 5, or 10 mg)
Number of subjects: 240
Study 8021909 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) (12.5 mg)
Number of subjects: 240
Study 8021909 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) (25 mg)
Number of subjects: 240
Study 8021909 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nebivolol and HCTZ
Number of subjects: 240
Study 8021909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 2738226 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing unit with therapeutic nursing focus
Number of subjects: 0
Study 2738226 — intervention group
Group type: COMPARATOR
Intervention: Acute hospital wards
Number of subjects: 0
Study 4555654 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim
Number of subjects: 339
Study 4555654 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 339
Study 4555654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 339
Study 4555654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 339
Study 31376435 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Thrombin (Human) Grifols (TTH-Grifols)
Number of subjects: 205
Study 28669689 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (epoetin β; mean dose 6000 IU per week)
Number of subjects: 48
Study 28669689 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0·9% NaCl)
Number of subjects: 48
Study 25279395 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX 0.2% rinse with alcohol (CHX1)
Number of subjects: 70
Study 25279395 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX 0.2% rinse without alcohol (CHX2)
Number of subjects: 70
Study 25279395 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX 0.2% rinse with antidiscolouration system (CHX3)
Number of subjects: 70
Study 25279395 — intervention group
Group type: COMPARATOR
Intervention: Saline rinse (CTRL)
Number of subjects: 70
Study 23439901 — intervention group
Group type: EXPERIMENTAL
Intervention: SBME mastery learning for infant lumbar puncture (ILP)
Number of subjects: 200
Study 23439901 — intervention group
Group type: COMPARATOR
Intervention: Control group for ILP (no SBME mastery learning)
Number of subjects: 200
Study 23439901 — intervention group
Group type: EXPERIMENTAL
Intervention: SBME mastery learning for child intravenous line placement (CIV)
Number of subjects: 200
Study 23439901 — intervention group
Group type: COMPARATOR
Intervention: Control group for CIV (no SBME mastery learning)
Number of subjects: 200
Study 21739598 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral antioxidant supplementation (900 IU of alpha‐tocopherol, 200 mg of ascorbic acid, and 600 mg of alpha‐lipoic acid)
Number of subjects: 53
Study 21739598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 19545481 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based mindfulness training (twice-weekly sessions for 5 weeks, plus home practice)
Number of subjects: 22
Study 19545481 — intervention group
Group type: COMPARATOR
Intervention: Waiting list for therapy
Number of subjects: 22
Study 16481635 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation (1000 mg of elemental calcium as calcium carbonate with 400 IU of vitamin D3 daily)
Number of subjects: 36282
Study 16481635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study 15318466 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 5% with nitrous oxide (N2O) 65% in O2
Number of subjects: 44
Study 15318466 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2 mg kg(‐1) intravenously
Number of subjects: 44
Study 11522563 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing 544 kJ x kg(‐1) x d(‐1) with 65% of nonprotein energy as carbohydrate
Number of subjects: 62
Study 11522563 — intervention group
Group type: COMPARATOR
Intervention: Formula containing 544 kJ x kg(‐1) x d(‐1) with 35% of nonprotein energy as carbohydrate
Number of subjects: 62
Study 11522563 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing 648 kJ x kg(‐1) x d(‐1) with 35% of nonprotein energy as carbohydrate
Number of subjects: 62
Study 11522563 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing 648 kJ x kg(‐1) x d(‐1) with 65% of nonprotein energy as carbohydrate
Number of subjects: 62
Study 9300474 — intervention group
Group type: EXPERIMENTAL
Intervention: Roller pump
Number of subjects: 46
Study 9300474 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pump
Number of subjects: 46
Study 8282920 — intervention group
Group type: EXPERIMENTAL
Intervention: Erection enhancement pill
Number of subjects: 20
Study 8282920 — intervention group
Group type: EXPERIMENTAL
Intervention: Erection detraction pill
Number of subjects: 20
Study 8282920 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 20
Study 3553039 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 22
Study 3553039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 29929437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - participated in six group sessions with an active peer model, received exercise prescription and PA information
Number of subjects: 52
Study 29929437 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Group (ACG) - received health information
Number of subjects: 52
Study 27313282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 10942
Study 27313282 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10942
Study 24694983 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0·5 mg twice daily for patients >70 kg or 0·5 mg once daily for patients ≤70 kg)
Number of subjects: 240
Study 24694983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 22541841 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naloxone 5 mg
Number of subjects: 28
Study 22541841 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naloxone 20 mg
Number of subjects: 28
Study 22541841 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naloxone 40 mg
Number of subjects: 28
Study 22541841 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naloxone 80 mg
Number of subjects: 28
Study 22541841 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naloxone 120 mg
Number of subjects: 28
Study 22541841 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal naloxone (dose not specified)
Number of subjects: 28
Study 22541841 — intervention group
Group type: COMPARATOR
Intervention: Intravenous naloxone 1 mg
Number of subjects: 28
Study 20822879 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental factors
Number of subjects: 310
Study 20822879 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent substance use severity
Number of subjects: 310
Study 20822879 — intervention group
Group type: EXPERIMENTAL
Intervention: Externalizing disorders
Number of subjects: 310
Study 18392039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry extract tablets
Number of subjects: 47
Study 18392039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 16019862 — intervention group
Group type: EXPERIMENTAL
Intervention: Local hyperthermia treatment (30-min sessions twice a week for 5 weeks, total of 20 sessions at 39-40 degrees C)
Number of subjects: 60
Study 16019862 — intervention group
Group type: COMPARATOR
Intervention: Intra-plaque infiltrations using 10 mg verapamil (one infiltration once a week for 3 months)
Number of subjects: 60
Study 12969043 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrococcygeal local anaesthesia
Number of subjects: 60
Study 12969043 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 60
Study 10807619 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate 500 microgram twice daily
Number of subjects: 751
Study 10807619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 751
Study 8806933 — intervention group
Group type: COMPARATOR
Intervention: 10% glucose (CHO)
Number of subjects: 6
Study 8806933 — intervention group
Group type: COMPARATOR
Intervention: 4.3% medium-chain triglycerides (MCTs)
Number of subjects: 6
Study 8806933 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glucose + 4.3% MCTs (CHO+MCT)
Number of subjects: 6
Study 1640130 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of midazolam
Number of subjects: 41
Study 1640130 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection followed by continuous infusion of midazolam
Number of subjects: 41
Study 6696291 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled diphemanil (2 mg)
Number of subjects: 20
Study 6696291 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 20
Study 29395182 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation in infancy
Number of subjects: 1018
Study 29395182 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency with or without anemia at 12 or 18 months
Number of subjects: 1018
Study 27876353 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell (MNC) injections intradermally
Number of subjects: 38
Study 27876353 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections intradermally
Number of subjects: 38
Study 24872562 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI analysis of prefrontal cortex value signals while imagining pleasure from engaging activities and snack foods
Number of subjects: 0
Study 24872562 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI analysis of prefrontal cortex value signals
Number of subjects: 0
Study 22481421 — intervention group
Group type: COMPARATOR
Intervention: Procaine penicillin (50,000 units/kg OD IM) and gentamicin (5 mg/kg OD IM)
Number of subjects: 434
Study 22481421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (50 mg/kg OD IM)
Number of subjects: 434
Study 22481421 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trimethoprim-sulfamethoxazole (TMP-SMX) at 10 mg/kg/day divided twice daily and gentamicin IM OD
Number of subjects: 434
Study 19917596 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused treatment
Number of subjects: 353
Study 19917596 — intervention group
Group type: COMPARATOR
Intervention: Health education group treatment
Number of subjects: 353
Study 18401254 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedatives and opioids
Number of subjects: 549
Study 18401254 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedatives
Number of subjects: 549
Study 18401254 — intervention group
Group type: EXPERIMENTAL
Intervention: NMBAs
Number of subjects: 549
Study 15944633 — intervention group
Group type: EXPERIMENTAL
Intervention: Video informed consent
Number of subjects: 0
Study 15944633 — intervention group
Group type: COMPARATOR
Intervention: Traditional verbal informed consent
Number of subjects: 0
Study 12857428 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1500 mg/day)
Number of subjects: 17
Study 12857428 — intervention group
Group type: COMPARATOR
Intervention: Control (no metformin)
Number of subjects: 17
Study 10475317 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus fentanyl (100 microg) with 1.5% lidocaine and epinephrine test dose
Number of subjects: 80
Study 10475317 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with 1.5% lidocaine and epinephrine test dose
Number of subjects: 80
Study 10475317 — intervention group
Group type: COMPARATOR
Intervention: Saline control group (3 mL isotonic sodium chloride solution)
Number of subjects: 80
Study 10475317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (propofol and propofol-fentanyl) with test dose
Number of subjects: 80
Study 7815584 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% and 20% papaverine base gel applied to the scrotum, perineum, and penis
Number of subjects: 20
Study 7815584 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 20
Study 7815584 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% and 20% papaverine base gel
Number of subjects: 20
Study 1941852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional interferon alpha-2b (1.5 million units, nine injections)
Number of subjects: 11
Study 1941852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional interferon alpha-2b
Number of subjects: 11
Study 7017781 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluproquazone (100 mg)
Number of subjects: 31
Study 7017781 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg)
Number of subjects: 31
Study 30589790 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-Carnitine 3000 mg/day for 2 months
Number of subjects: 20
Study 30589790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27680418 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pitch computed tomography (HPCT)
Number of subjects: 55
Study 27680418 — intervention group
Group type: COMPARATOR
Intervention: Conventional multidetector computed tomography (MDCT)
Number of subjects: 55
Study 25534726 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg nemonoxacin
Number of subjects: 28
Study 25534726 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg nemonoxacin
Number of subjects: 28
Study 25534726 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg nemonoxacin
Number of subjects: 28
Study 25534726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23208803 — intervention group
Group type: EXPERIMENTAL
Intervention: Medpor (porous polyethylene) implantation for inferior turbinate reconstruction
Number of subjects: 19
Study 21107298 — intervention group
Group type: EXPERIMENTAL
Intervention: SCE‐A vaginal cream (1 g once daily for 7 days, then twice weekly for 27 days)
Number of subjects: 0
Study 21107298 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg SCE‐A oral tablets (once daily for 27 days)
Number of subjects: 0
Study 19365317 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery
Number of subjects: 0
Study 19365317 — intervention group
Group type: COMPARATOR
Intervention: Open antireflux surgery
Number of subjects: 0
Study 19365317 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy (proton pump inhibitors)
Number of subjects: 0
Study 19365317 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete wrap (Nissen's fundoplication)
Number of subjects: 0
Study 19365317 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial fundoplication (Toupet)
Number of subjects: 0
Study 19365317 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux surgery
Number of subjects: 0
Study 17065847 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 1.0 g daily for 6 months
Number of subjects: 119
Study 17065847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 14742366 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. parecoxib 40 mg followed by oral valdecoxib 40 mg
Number of subjects: 263
Study 14742366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 12681184 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Flow (IF)
Number of subjects: 125
Study 12681184 — intervention group
Group type: EXPERIMENTAL
Intervention: Medijet (MJ)
Number of subjects: 125
Study 10467840 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum adenosine deaminase (ADA) activity
Number of subjects: 20
Study 10467840 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ADA level > or = 53.76 U/l
Number of subjects: 20
Study 7786522 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% Tiacrilast hydrogel
Number of subjects: 31
Study 7786522 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel alone
Number of subjects: 31
Study 2079774 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (mean blood alcohol level approximately 69.5 mg%; SE 6.20 mg%)
Number of subjects: 17
Study 540702 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (I) (0.02 microgram/kg/min)
Number of subjects: 12
Study 540702 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (DP) (5 microgram/kg/min)
Number of subjects: 12
Study 540702 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (DB) (5 microgram/kg/min)
Number of subjects: 12
Study 30770519 — intervention group
Group type: EXPERIMENTAL
Intervention: IV golimumab 2 mg/kg at weeks 0, 4, 12, and 20
Number of subjects: 474
Study 30770519 — intervention group
Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 474
Study 30770519 — intervention group
Group type: EXPERIMENTAL
Intervention: IV golimumab
Number of subjects: 474
Study 28096029 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD‐GRIP intervention
Number of subjects: 24
Study 26433431 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (4 mg/kg once)
Number of subjects: 100
Study 26433431 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (15 mg/kg every 12 h)
Number of subjects: 100
Study 23400985 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia (CSE)
Number of subjects: 800
Study 23400985 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 800
Study 21231927 — intervention group
Group type: EXPERIMENTAL
Intervention: FCM (Fludarabine, Cyclophosphamide, Mitoxantrone)
Number of subjects: 52